论文部分内容阅读
随着化疗方案的改进及靶向药物的出现,使部分恶性血液病患者获得了长期生存。但对于难治复发恶性血液病患者,再次行异基因造血干细胞移植(HSCT)仍是有效的重要手段之一。本研究对我院2010年10月至2015年1月行挽救性二次移植治疗的16例恶性血液病患者进行分析。现报道如下。1病例和方法所有16例患者均来自于苏州大学附属第一医院,均为接受自体干细胞移植或者异基因HSCT后
With the improvement of chemotherapy regimens and the emergence of targeted drugs, some patients with hematologic malignancies have long-term survival. However, for all patients with refractory recurrent hematologic malignancies, allogeneic hematopoietic stem cell transplantation (HSCT) is still an effective method. This study analyzed 16 patients with hematologic malignancies undergoing salvage secondary transplant in our hospital from October 2010 to January 2015. Report as follows now. 1 cases and methods All 16 patients were from the First Affiliated Hospital of Soochow University, are receiving autologous stem cell transplantation or allogeneic HSCT